Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Februar 2025

Genmab — Februar 2025

Planlagt Fastgjort Låst Flyttet Genmab
699 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • exitnuE Offline
    exitnuE Offline
    exitnu
    wrote on sidst redigeret af
    #319

    God morgen 🙂

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #320

      Jan mentioning that Epkinly is the most advanced candidate for I&I 'and we are in discussions' with AbbVie' on that is another signal this may go forward, think we have to raise the chance that this will happen

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #321

        Jan on GEN1042 -I can tell you that not only we, but also Biontech is very excited about what we have seen up to now with 1042 -- great potential for combining 1042 with different ADCs -- we'll need a bit more data to get a better feeling for durability, but a high level of excitement.

        1 Reply Last reply
        0
        • E Offline
          E Offline
          E_L
          wrote on sidst redigeret af
          #322

          so even though we still have to be patient for a while, to me it does still sounds
          very positive for now

          1 Reply Last reply
          0
          • E Offline
            E Offline
            E_L
            wrote on sidst redigeret af
            #323

            Ahmadi confirmed lahn 's scoop that Epcoritamab got the NCCN
            Category 2A designation with GemOX

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #324

              So: Effective January 1, 2025, Genmab and Pfizer agreed to amend
              the License and Collaboration Agreement and
              the Joint Commercialization Agreement for
              Tivdak, assigning Genmab sole responsibility
              for the development and commercialization of
              Tivdak for second line plus recurrent or metastatic
              cervical cancer in Europe and all other
              regions globally, excluding the United States and the China region.

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #325

                -this means they will need to build european sales force, which they will need anyway for a similar population for Rina-S but also for Acasunlimab

                1 Reply Last reply
                0
                • B Offline
                  B Offline
                  bibob
                  wrote on sidst redigeret af
                  #326

                  God morgen. 🙂

                  1 Reply Last reply
                  0
                  • SolsenS Offline
                    SolsenS Offline
                    Solsen
                    wrote on sidst redigeret af
                    #327

                    @EL
                    Or they join with others

                    1 Reply Last reply
                    0
                    • J Offline
                      J Offline
                      JKY_VH
                      wrote on sidst redigeret af
                      #328

                      Jyske om dagens aktie Genmab "Vi vurderer, at på aktiens nuværende kursniveau får investorer hele pipelinen samt nogle af de allerede lancerede produkter gratis." https://www.jyskebank.dk/finansnyt/morgennyt/7b36b205-0095-4232-9f06-b95718b64493/!ut/p/z1/rVRdc6IwFP0t--BjJgFikL4hdq3id3UleXGApjQtCRYR6_76DTI7S53t2p3KS3Jv7j3nzJ17gAwGkKmwFElYiEyFqY4pI5uZ2cNG5x5N-rOuhebLkf990VsYy6kNf0DahdTdR8PBAa4vVTP9jD74XKT72aUSqinsDymwAdel4Ae4Ulkutf77CnEbiwdI7cgikYnaACGnDbBpmcB5RARETts2OhHB2LHg3SUGH_2NYe2NN_PV7UL37g

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #329

                        but than it wouldn't really make sense to take over from Pfizer ? they could have joined them
                        ?

                        1 Reply Last reply
                        0
                        • SolsenS Offline
                          SolsenS Offline
                          Solsen
                          wrote on sidst redigeret af
                          #330

                          You know with JNJ or Abbvie to make one BP 😉

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #331

                            I know Jan said he was looking for M&A, but i am not sure he was looking to buy JNJ or Abbvie Solsen 😄

                            1 Reply Last reply
                            0
                            • A Offline
                              A Offline
                              Aaanditsgone
                              wrote on sidst redigeret af
                              #332

                              Tæller option exercise fees som milestone/reimburdement revenue? Undrer mig lidt over, at spændet ikke er større, hvis der potentielt er $150 m forskel på et ja eller nej. Men den afgift er måske slet ikke med i guidance?

                              1 Reply Last reply
                              0
                              • A Offline
                                A Offline
                                Aaanditsgone
                                wrote on sidst redigeret af
                                #333

                                (de guider med 140-185 m)

                                1 Reply Last reply
                                0
                                • J Offline
                                  J Offline
                                  JKY_VH
                                  wrote on sidst redigeret af
                                  #334
                                  • 3,75%, lad os håbe at det er første spæde skridt ud af den kursmæssige ”ørkenvandring” vi har oplevet de sidste par år.
                                  1 Reply Last reply
                                  0
                                  • J Offline
                                    J Offline
                                    JKY_VH
                                    wrote on sidst redigeret af
                                    #335

                                    +5%, bliver der mon tændt for det lange lys nu?

                                    1 Reply Last reply
                                    0
                                    • R Offline
                                      R Offline
                                      Raun
                                      wrote on sidst redigeret af
                                      #336

                                      Det tror jeg desværre ikke @JKY_VH

                                      1 Reply Last reply
                                      0
                                      • W Offline
                                        W Offline
                                        w
                                        wrote on sidst redigeret af
                                        #337

                                        Tågelyset er fortsat tændt

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #338

                                          From the annual report on the authorization to acquire treasury shares: Shares available for repurchase as of December 31, 2024 1,678,147. So they can start buying I guess, but not for the full 1.9mn they intend to buy, and then they can get additional AGM approval for the last part
                                          in March?

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper